FDA Extends Ruxolitinib Cream Review Period for Pediatric AD ...Middle East

The supplemental application is based on data from a phase 3 study of children aged 2-12 years with mild-to-moderate AD, randomly assigned to 0.75% or 1.5% ruxolitinib or a vehicle. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Extends Ruxolitinib Cream Review Period for Pediatric AD )

Also on site :

• Padres Release Jason Heyward
• UNHCR: 2.5M refugees need resettlement as US freezes program
• Adidas Has 'Sleek' $180 Running Shoes for Just $90, and Reviewers Say They Feel Like They’re 'Walking On Clouds'